

Richard Layese

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3762753/publications.pdf>

Version: 2024-02-01

45
papers

1,772
citations

430874

18
h-index

289244

40
g-index

45
all docs

45
docs citations

45
times ranked

3014
citing authors

#	ARTICLE	IF	CITATIONS
1	Eradication of Hepatitis C Virus Infection in Patients With Cirrhosis Reduces Risk of Liver and Non-Liver Complications. <i>Gastroenterology</i> , 2017, 152, 142-156.e2.	1.3	420
2	Incidence of Hepatocellular Carcinoma After Direct Antiviral Therapy for HCV in Patients With Cirrhosis Included in Surveillance Programs. <i>Gastroenterology</i> , 2018, 155, 1436-1450.e6.	1.3	183
3	Validation of the AFP model as a predictor of HCC recurrence in patients with viral hepatitis-related cirrhosis who had received a liver transplant for HCC. <i>Journal of Hepatology</i> , 2017, 66, 552-559.	3.7	166
4	Validation of Baveno VI Criteria for Screening and Surveillance of Esophageal Varices in Patients With Compensated Cirrhosis and a Sustained Response to Antiviral Therapy. <i>Gastroenterology</i> , 2019, 156, 997-1009.e5.	1.3	100
5	Early detection and curative treatment of hepatocellular carcinoma: A cost-effectiveness analysis in France and in the United States. <i>Hepatology</i> , 2017, 65, 1237-1248.	7.3	93
6	Compliance With Hepatocellular Carcinoma Surveillance Guidelines Associated With Increased Lead-Time Adjusted Survival of Patients With Compensated Viral Cirrhosis: A Multi-Center Cohort Study. <i>Gastroenterology</i> , 2018, 155, 431-442.e10.	1.3	81
7	Origin, HDV genotype and persistent viremia determine outcome and treatment response in patients with chronic hepatitis delta. <i>Journal of Hepatology</i> , 2020, 73, 1046-1062.	3.7	79
8	Nomogram for individualized prediction of hepatocellular carcinoma occurrence in hepatitis C virus cirrhosis (ANRS CO12 CirVir). <i>Hepatology</i> , 2016, 64, 1136-1147.	7.3	75
9	Bacterial infection in compensated viral cirrhosis impairs 5-year survival (ANRS CO12 CirVir) Tj ETQq1 1 0.784314 rgBT /Overlock 10 T	2.1	59
10	Self-reported loss of smell without nasal obstruction to identify COVID-19. The multicenter Coronasmia cohort study. <i>Journal of Infection</i> , 2020, 81, 614-620.	3.3	55
11	The Mini Mental State Examination at the Time of Alzheimer's Disease and Related Disorders Diagnosis, According to Age, Education, Gender and Place of Residence: A Cross-Sectional Study among the French National Alzheimer Database. <i>PLoS ONE</i> , 2014, 9, e103630.	2.5	55
12	Personalized surveillance for hepatocellular carcinoma in cirrhosis using machine learning adapted to HCV status. <i>Journal of Hepatology</i> , 2020, 73, 1434-1445.	3.7	52
13	Prognostic value of viral eradication for major adverse cardiovascular events in hepatitis C cirrhotic patients. <i>American Heart Journal</i> , 2018, 198, 4-17.	2.7	49
14	New cancer cases at the time of SARS-Cov2 pandemic and related public health policies: A persistent and concerning decrease long after the end of the national lockdown. <i>European Journal of Cancer</i> , 2021, 150, 260-267.	2.8	37
15	Extrahepatic cancers are the leading cause of death in patients achieving hepatitis B virus control or hepatitis C virus eradication. <i>Hepatology</i> , 2018, 68, 1245-1259.	7.3	33
16	Clinical spectrum and short-term outcome of adult patients with purpura fulminans: a French multicenter retrospective cohort study. <i>Intensive Care Medicine</i> , 2018, 44, 1502-1511.	8.2	30
17	Human Immunodeficiency Virus/Hepatitis C Virus (HCV) Co-infected Patients With Cirrhosis Are No Longer at Higher Risk for Hepatocellular Carcinoma or End-stage Liver Disease as Compared to HCV Mono-infected Patients. <i>Hepatology</i> , 2019, 70, 939-954.	7.3	28
18	Colorectal cancer (CRC) monitoring by 6-monthly 18FDG-PET/CT: an open-label multicentre randomised trial. <i>Annals of Oncology</i> , 2018, 29, 931-937.	1.2	21

#	ARTICLE	IF	CITATIONS
19	Long-term Quality of Life in Adult Patients Surviving Purpura Fulminans: An Exposed-Unexposed Multicenter Cohort Study. <i>Clinical Infectious Diseases</i> , 2019, 69, 332-340.	5.8	19
20	Influence of Progenitorâ€Derived Regeneration Markers on Hepatitis C Virusâ€Related Cirrhosis Outcome (ANRS CO12 CirVir Cohort). <i>Hepatology</i> , 2018, 68, 1534-1548.	7.3	16
21	Nonâ€virological factors are drivers of hepatocellular carcinoma in viro-suppressed hepatitis B cirrhosis: Results of <sc>ANRS CO</sc>12 CirVir cohort. <i>Journal of Viral Hepatitis</i> , 2019, 26, 384-396.	2.0	16
22	Early hepatocellular carcinoma detection using magnetic resonance imaging is cost-effective in high-risk patients with cirrhosis. <i>JHEP Reports</i> , 2022, 4, 100390.	4.9	15
23	Virologic control and severity of liver disease determine survival after radiofrequency ablation of hepatocellular carcinoma on cirrhosis. <i>Digestive and Liver Disease</i> , 2019, 51, 86-94.	0.9	14
24	Long-term quality of life in necrotizing soft-tissue infection survivors: a monocentric prospective cohort study. <i>Annals of Intensive Care</i> , 2021, 11, 102.	4.6	12
25	Prognostic factors of survival in <sc>HIV</sc>/<sc>HCV</sc> coâ€infected patients with hepatocellular carcinoma: The <sc>CARCINOVIC</sc> Cohort. <i>Liver International</i> , 2019, 39, 136-146.	3.9	9
26	HCV eradication reduces the occurrence of major adverse cardiovascular events in hepatitis C cirrhotic patients: data from the prospective ANRS CO12 CirVir cohort. <i>Journal of Hepatology</i> , 2017, 66, S20-S21.	3.7	7
27	Elevated adiponectin and sTNFRII serum levels can predict progression to hepatocellular carcinoma in patients with compensated HCV1 cirrhosis. <i>European Cytokine Network</i> , 2018, 29, 112-120.	2.0	7
28	Multichamber Dysfunction in Children and Adolescents With Severe Obesity: A Cardiac Magnetic Resonance Imaging Myocardial Strain Study. <i>Journal of Magnetic Resonance Imaging</i> , 2021, 54, 1393-1403.	3.4	7
29	Effect of lockdown on digestive system cancer care amongst older patients during the first wave of COVID-19: The CADIGCOVAGE multicentre cohort study. <i>Digestive and Liver Disease</i> , 2022, 54, 10-18.	0.9	7
30	P0600 : Predictive factors of cirrhosis, hepatic decompensation and hepatocellular carcinoma in patients with chronic hepatitis delta. <i>Journal of Hepatology</i> , 2015, 62, S541-S542.	3.7	5
31	Non-invasive fibrosis tests to predict complications in compensated post-hepatitis C cirrhosis. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2020, 44, 524-531.	1.5	5
32	Impact of cirrhosis aetiology on incidence and prognosis of hepatocellular carcinoma diagnosed during surveillance. <i>JHEP Reports</i> , 2021, 3, 100285.	4.9	4
33	New Recommendations of Baveno VI Conference for the Screening of Portal Hypertension: An Independent Sequential Validation in Patients with Compensated Viral Cirrhosis Taking into Account Virological Status (Anrs Co12 Cirvir Cohort). <i>Journal of Hepatology</i> , 2016, 64, S178.	3.7	3
34	Prospective Evidence That Hepatocellular Carcinoma Surveillance in Patients with Compensated Viral Cirrhosis Increases the Probability of Curative Treatment and Survival Taking into Account Lead-Time Bias (Anrs Co12 Cirvir Cohort). <i>Journal of Hepatology</i> , 2016, 64, S194-S195.	3.7	2
35	HCV Eradication in Primary or Secondary Prevention Optimizes Hepatocellular Carcinoma Curative Management. <i>Cancer Prevention Research</i> , 2021, 14, 581-592.	1.5	2
36	Colorectal cancer (CRC) patients surveyed by 18FDGPET-CT (PET-CT): An open-label multicenter randomized trial (NCT 00624260).. <i>Journal of Clinical Oncology</i> , 2017, 35, 3520-3520.	1.6	2

#	ARTICLE	IF	CITATIONS
37	P0328 : Incidence, characteristics and determinants of primary liver cancer occurring during surveillance of compensated HCV cirrhosis according to sustained virological response (ANRS CO12) Tj ETQq1 1 0.784314 rgBT /Overlock 10	3.7	1
38	P0579 : Epidemiological, clinical and virological features of hepatitis delta virus infection in France. Journal of Hepatology, 2015, 62, S532-S533.	3.7	1
39	Early Detection and Curative Treatment of Hepatocellular Carcinoma: A Cost Effectiveness Analysis Based on Prospective French Cohort (ANRS CO12 CirVir and CHANGH). Journal of Hepatology, 2016, 64, S466.	3.7	1
40	Identifying residual risk of hepatocellular carcinoma following hepatitis C virus eradication in compensated cirrhosis: decision-tree and random forest models developed in the French multicenter prospective ANRS CO12 CirVir cohort. Journal of Hepatology, 2017, 66, S21-S22.	3.7	1
41	Extrahepatic Cancer is the Second Cause of Non Liver-Related Death in Patients with Compensated Viral Cirrhosis and is Associated with Viral Replication (ANRS CO12 CirVir Prospective Cohort). Journal of Hepatology, 2016, 64, S273.	3.7	0
42	The Benefits of Virosuppression on Progression of Portal Hypertension in Patients with Compensated Viral Cirrhosis (ANRS CO12 CirVir Cohort). Journal of Hepatology, 2016, 64, S655-S656.	3.7	0
43	Viral Suppression is Not a risk Factor for CKD in Viral Cirrhosis (ANRS CO12 CirVir Prospective) Tj ETQq1 1 0.784314 rgBT /Overlock 10	3.7	0
44	HIV/HCV-coinfected cirrhotic patients are no longer at higher risk of hepatocellular carcinoma or end-stage liver disease as compared to HCV-monoinfected patients (ANRS CO12 CirVir and ANRS CO13) Tj ETQq0 0.0 rgBT /Overlock 10	3.7	0
45	Reply. Gastroenterology, 2019, 156, 289-290.	1.3	0